Lactobacillus Farciminis and Hyperalgesia

This study has been completed.
Sponsor:
Information provided by:
Lallemand SAS
ClinicalTrials.gov Identifier:
NCT00852865
First received: February 25, 2009
Last updated: April 30, 2009
Last verified: April 2009
  Purpose

We want to analyse a possible effect of o dialy consumption of Lactobacillus farciminis on a hyperalgesia on response to thermal stimulation. A comparaison of results before and after three weeks of treatment will be made.


Condition Intervention Phase
Inflammation
Pain
Drug: Lactobacillus farciminis
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effect of a Dialy Consumption of a Probiotic (Lactobacillus Farciminis) on Hyperalgesia in Response to Thermal Stimulation

Resource links provided by NLM:


Further study details as provided by Lallemand SAS:

Primary Outcome Measures:
  • Measurement of the mchanical pain threshold in primary and secondary areas by using a punctate stimulus. [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Measurement of cutaneous temperature of hyperalgesia areas [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: February 2009
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
24 healthy volunteers consuming L.farciminis during three weeks
Drug: Lactobacillus farciminis
1 capsule per day. Each capsule containing 4*109 CFU
Placebo Comparator: 2
24 healthy volunteers consuming placebo during three weeks
Drug: Placebo
1 capsule per day

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

  • consumption of yogurts
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00852865

Locations
France
Cpc / Cic-Inserm 501
Clermont-Ferrand, France, 63000
Sponsors and Collaborators
Lallemand SAS
Investigators
Principal Investigator: Claude DUBRAY, Professor CPC/CIC-INSERM 501
  More Information

No publications provided

Responsible Party: Henri DURAND, LALLEMAND SAS
ClinicalTrials.gov Identifier: NCT00852865     History of Changes
Other Study ID Numbers: HN 08-17, 2008-A01380-55
Study First Received: February 25, 2009
Last Updated: April 30, 2009
Health Authority: France: Direction Générale de la Santé

Keywords provided by Lallemand SAS:
Inflammation
Pain

Additional relevant MeSH terms:
Hyperalgesia
Inflammation
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Pathologic Processes

ClinicalTrials.gov processed this record on July 31, 2014